Introduction
The majority of patients with chronic kidney disease are anaemic. Iron deficiency should be corrected before treatment with recombinant human erythropoietin (rhuEpo) or novel erythropoiesis stimulating protein (NESP) is initiated. During maintenance rhuEpo or NESP therapy, iron supplementation is needed to prevent hyporesponsiveness to these drugs. On the other hand, iron supplementation is not without sideeffects, particularly if high dose intravenous (i.v.) iron is administered.
Effects of iron overload on the cardiovascular system

Animal studies
In vivo studies showed that iron overload may result in cardiomyopathy, manifested by ventricular arrhythmias and heart failure w1x. Alterations of glutathione peroxidase activity and increases in cytotoxic aldehyde concentrations in the heart may contribute to ironinduced heart failure w1x. Extracellular hydroxyl radical formation is not responsible for iron-mediated cardiotoxicity w2x. This does not, however, exclude that myocardial iron toxicity is the result of free radical damage generated intracellularly. Experimental data demonstrate that vitamin E (a-tocopherol) completely inhibits mitochondrial iron toxicity without affecting iron uptake or release. In contrast, the mild cardioprotective effect of ascorbate occurs in association with decreased cellular iron uptake w3x.
Iron is an essential catalyst in the oxidation process. Macrophages require iron to oxidize low-density lipoprotein (LDL) cholesterol w4x. Rats fed a highcholesterol, iron-deficient diet have lower levels of antibodies to oxidized LDL cholesterol, and less aortic atherosclerosis than rats fed a high-iron diet w5x.
Iron overload augments the development of atherosclerotic lesions in rabbits on high-cholesterolaemic or normocholesterolaemic diet w6x.
In contrast, a recent study by Kirk et al. w7x suggests that elevated serum and tissue levels of iron induced by a 2% carbonyl iron diet are not atherogenic in apoE-deficient mice. Dietary iron overload caused a 30% rise in plasma triglycerides and cholesterol, but reduced the severity of atherosclerosis by 50%. Failure to elevate hepatic levels of heme oxygenase mRNA (induced by oxidative insults) and of protein-bound dityrosine and ortho-tyrosine (markers of metalcatalyzed oxidative damage) also does not support the hypothesis that elevated levels of tissue iron promote LDL oxidation and oxidative stress in vivo w7x. However, iron overload in apoE-deficient mice was induced by the oral route, whereas it is probably the intravenous route of iron administration that is particularly dangerous in dialysis patients.
Iron status and cardiovascular disease in man
The amount of aortic iron deposition is directly associated with the severity of atherosclerosis w8x, and cellular iron overload causes ventricular arrhythmia and heart failure w9x. Kiechl et al. w10x found a strong correlation between serum ferritin concentration and the likelihood of new carotid lesion formation along with the progression of atherosclerotic lesions present at baseline. Participants in the study, whose iron stores declined, showed less carotid atherosclerosis. The ratio of the serum concentration of transferrin receptor to that of ferritin (TfRuferritin) correlates with the risk of acute myocardial infarction (AMI). Patients with TfRuferritin ratios in the lowest tertile had almost three times the risk of AMI compared with patients in the top tertile w11x. A serum ferritin concentration of P200 mgul may double the risk of AMI in elderly patients, particularly in the presence of other risk factors such as hypercholesterolaemia, diabetes anduor smoking w12x. However, the majority of human observational studies do not support the hypothesis that high levels of body iron stores increase the risk of coronary heart disease w13,14x. One possible explanation could be that serum ferritin in end-stage renal disease is not only elevated due to iron overload, but also due to infection or inflammation, which are additional risk factors for cardiovascular disease w15x. 
Effect of iron depletion on cardiovascular disease
Experimental and human data suggest that iron depletion protects against ischaemic heart disease w16x. Even small elevations of serum ferritin are associated with an increase in carotid atherosclerosis in men and in women with intact kidney function w10x. Volunteer blood donation is associated with significant decrease in atherosclerosis and vascular events w17,18x.
Iron may cause cardiovascular disease by oxidation of LDL cholesterol anduor endothelial dysfunction. Lowering of body iron stores by blood letting results in a 44% decline in serum ferritin concentration, a 20% decrease in maximal oxidation velocity, and a 33% increase in oxidation resistance w19x. Moreover, iron chelation by deferoxamine improves endothelial function in patients with coronary artery disease w20x. Iron depletion protects against ischaemic heart disease, explaining the low risk observed in menstruating women w21x.
Genetic disease association studies
Homozygosity for the Cys282Tyr or the His63Asp mutation in the haemochromatosis gene (gene locus: HFE) confers a substantial risk for iron overload, whereas heterozygous individuals may present with slightly elevated iron stores w22x. Increased cardiovascular event rates were reported in individuals with an iron loading genotype w23-25x. The HFE Cys282Tyr mutation was associated with a relative risk factor for AMI of 2.3 in men w24x and with an increased risk for cardiovascular death in women w23x. However, several small studies did not find a relationship between HFE variants and cardiovascular disease w26,28x, although Hetet et al. reported some effect of HFE His63Asp mutation on carotid atherosclerosis of smokers w27x. Furthermore, Rossi et al. w26x could not find an association of HFE Cys282Tyr with carotid artery plaque formation, but subgroup analysis showed some effect of ferritin levels on atherosclerosis in women w26x. A small study also failed to show an association of both HFE mutations on premature atherosclerosis w28x. Thus, controversy still exists regarding the association of iron loading genotypes with cardiovascular disease outcomes.
Ferritin levels and cardiovascular disease in end-stage renal disease
Iron potentially contributes to cardiovascular complications in end-stage renal disease patients. Serum ferritin is a marker for morbidity and mortality in haemodialysis patients. An elevated serum ferritin concentration is a strong predictor of hospitalization, and an increase of 500 mgul in serum ferritin is associated with a 2.7-fold relative risk of death w29x. In our experience, haemodialysis patients with serum ferritin )600 mgul do show an increased overall 4-year mortality, even in the absence of elevated C-reactive protein w30x. Another study involving 5833 haemodialysis patients showed that patients who received more than ten 100 mg doses of i.v. iron over 6 months had a higher relative risk of hospitalization (1.12 vs 0.92) and death (1.11 vs 0.93) than haemodialysis patients receiving 10 or less doses of i.v. iron w31x.
Effect of vitamin E on iron-induced changes
A single oral dose of vitamin E attenuates lipid peroxidation in patients on haemodialysis receiving i.v. iron w32x. Vitamin E therapy reduces composite cardiovascular disease end-points and myocardial infarction in maintenance haemodialysis patients w33x.
Acute adverse events of high-dose intravenous iron
The use of parenteral iron dextran may result in anaphylactoid reactions occurring even at test doses. On the other hand, a negative dextran allergy test does not mean the patient will not have a reaction in the future w34x. A recent study w35x demonstrates the safety and efficacy of iron sucrose in 23 haemodialysis patients with hypersensitivity reactions to iron dextran. A total of 16 patients experienced mild reactions to iron dextran and seven patients developed severe complications such as hypotension with dyspnoea, or heart arrest (ns5) and bronchospasm, cough or dyspnoea (ns2). The authors prospectively examined adverse events and vital signs after administering 100 mg of i.v. iron sucrose in each of 10 consecutive dialysis treatment sessions. No serious adverse drug reactions after a total of 223 doses of iron sucrose were observed in these dialysis patients with hypersensitivity to iron dextran. Self-limited episodes of metallic taste occurred in one patient and apparent infusion raterelated pruritus occurred in another patient. It was concluded that iron sucrose at a dose of 100 mg can be administered safely and effectively by i.v. push (5 min) or infusion (15-30 min) without a test dose w35x. Hoigne et al. w36x analysed 160 000 doses of 100 mg iron sucrose administered to patients undergoing regular haemodialysis, calculated as 8100 patientyears. No cases of life-threatening adverse reactions occurred. There were five to seven instances of rapidly reversible hypotension, 10 cases of flushing, one case of urticaria and one case of vomiting with diarrhoea w36x.
An allergy event reporting rate of 3.3 cases per million doses per year has been published for iron gluconate, compared with a rate of 8.7 reported allergy events per million doses per year for iron dextran. There were no reported fatalities with iron gluconate among the reports of allergic events, in contrast to 31 fatalities among the 196 allergyuanaphylaxis cases reported with iron dextran w37x. In a prospective, crossover, blinded, placebo-and historically controlled study, 1117 maintenance haemodialysis patients were treated with both placebo and a single bolus of 125 mg iron gluconate. Of these patients, 73 (6.5%) had a history of hypersensitivity to iron dextran. The rate of blinded 'life-threatening' reactions was 0.09% (1u1117), indicating an important advance using iron gluconate as compared with iron dextran w38x.
In the study by Prakash et al. w39x, peritoneal dialysis patients received either iron dextran or iron sucrose infusions of 500 mg each, twice, 1 week apart. Both iron preparations were infused over 4-5 h if the patient remained asymptomatic after a test dose. One anaphylactic reaction was observed in each group. It is, however, unclear whether the severe adverse event occurring in one of the iron sucrose-treated patients was related to this iron preparation per se or to the large dose of iron sucrose administered. There was a trend toward increased peritonitis rates after high-dose iron infusions during the 6-month study period. According to Chandler et al. w40x, iron sucrose doses up to 300 mg may be given safely over 2 h, but doses of 500 mg should be administered as an infusion over P3.5 h. Side effects (vertigo, hypotension, lumbago, vomiting) occurred in 0.9% of the patients receiving 100 mg iron sucrose over a period of 10 min, but in 5.9% of the patients receiving 200 mg iron sucrose. Slower administration of this iron sucrose dose did not lead to any side effect w41x.
Iron overload and disturbed host defence
Finally, iron affects both bacterial virulence and host defence mechanisms, since iron is an important growth factor for bacteria and a prerequisite for clinically important infections. We found a significant inhibition of intracellular killing of bacteria by polymorphonuclear leukocytes in haemodialysis patients with serum ferritin levels )650 mgul (mean value 912 mgul) w42x.
Conclusion
Epidemiological data suggest that iron is an important factor in the process of atherosclerosis, but the exact mechanism and the sites of the interaction between macrophages, endothelial cells, iron and low-density lipoprotein are still unknown w43x. The 'iron hypothesis', suggesting that iron depletion protects against ischaemic heart disease, is biologically plausible w44x. On the other hand, end-stage renal disease patients require adequate iron therapy to benefit from treatment with rhuEpo or NESP. Optimizing the monitoring of iron parameters includes the determination of the percentage of hypochromic red blood cells w45x anduor the reticulocyte haemoglobin content w46x, in addition to ferritin and transferrin saturation. This may allow correction of renal anaemia on an individual basis, thereby lowering the iron need per patient and hopefully reducing acute adverse events and long-term complications of iron therapy.
